CDK4/6 Inhibitors in Melanoma: A Comprehensive Review.
Abemaciclib
CDK4
CDK4/6
CDK6
Palbociclib
Ribociclib
melanoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
28 05 2021
28 05 2021
Historique:
received:
02
05
2021
revised:
20
05
2021
accepted:
25
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Historically, metastatic melanoma was considered a highly lethal disease. However, recent advances in drug development have allowed a significative improvement in prognosis. In particular, BRAF/MEK inhibitors and anti-PD1 antibodies have completely revolutionized the management of this disease. Nonetheless, not all patients derive a benefit or a durable benefit from these therapies. To overtake this challenges, new clinically active compounds are being tested in the context of clinical trials. CDK4/6 inhibitors are drugs already available in clinical practice and preliminary evidence showed a promising activity also in melanoma. Herein we review the available literature to depict a comprehensive landscape about CDK4/6 inhibitors in melanoma. We present the molecular and genetic background that might justify the usage of these drugs, the preclinical evidence, the clinical available data, and the most promising ongoing clinical trials.
Identifiants
pubmed: 34071228
pii: cells10061334
doi: 10.3390/cells10061334
pmc: PMC8227121
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
CDK4 protein, human
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Invest Dermatol. 2009 Jan;129(1):175-83
pubmed: 18719612
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Nat Commun. 2019 Mar 26;10(1):1373
pubmed: 30914635
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
Clin Cancer Res. 2013 Oct 1;19(19):5320-8
pubmed: 24089445
Cancer Cell. 2018 Dec 10;34(6):893-905.e8
pubmed: 30537512
Mol Cell. 2012 Mar 9;45(5):669-79
pubmed: 22306294
Front Pharmacol. 2020 Nov 16;11:580251
pubmed: 33364954
Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87
pubmed: 11960696
Sci Transl Med. 2019 Aug 14;11(505):
pubmed: 31413145
Cancer Discov. 2017 Apr;7(4):424-441
pubmed: 28174173
Cancer Discov. 2018 May;8(5):568-581
pubmed: 29496664
Cancer. 2019 Feb 15;125(4):586-600
pubmed: 30561760
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Oncogene. 2017 Apr 20;36(16):2255-2264
pubmed: 27748766
Hered Cancer Clin Pract. 2021 Mar 25;19(1):21
pubmed: 33766116
Eur J Med Chem. 2019 Jun 15;172:143-153
pubmed: 30978559
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13312-7
pubmed: 11606789
Immun Ageing. 2020 Jun 3;17:16
pubmed: 32518575
Cell Rep. 2019 Mar 5;26(10):2667-2680.e7
pubmed: 30840889
Methods Mol Biol. 2016;1342:3-19
pubmed: 26254915
Cancer Res. 2019 May 1;79(9):2352-2366
pubmed: 30819666
Oncogene. 2006 Aug 28;25(38):5220-7
pubmed: 16936740
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Clin Pharmacokinet. 2018 Mar;57(3):335-344
pubmed: 28540640
Eur J Med Chem. 2020 Oct 15;204:112531
pubmed: 32712436
Drugs. 2021 Feb;81(3):317-331
pubmed: 33369721
J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S78-86
pubmed: 22018071
Int J Mol Sci. 2021 Apr 07;22(8):
pubmed: 33917086
J Biol Chem. 2013 Dec 6;288(49):35511-25
pubmed: 24163379
Int J Mol Sci. 2020 Sep 01;21(17):
pubmed: 32883002
Chin Clin Oncol. 2018 Dec;7(6):62
pubmed: 30180747
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Tumour Biol. 2012 Dec;33(6):2189-99
pubmed: 23001925
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
Lancet. 2020 Mar 7;395(10226):817-827
pubmed: 32145796
Onco Targets Ther. 2018 Oct 17;11:7095-7107
pubmed: 30410366
Oncogene. 2005 May 12;24(21):3459-71
pubmed: 15735667
Nature. 1995 Mar 9;374(6518):131-4
pubmed: 7877684
Mol Cell Biol. 2002 Jan;22(2):644-56
pubmed: 11756559
Breast Cancer Res Treat. 2020 Sep;183(2):479-487
pubmed: 32647939
Clin Cancer Res. 2016 Dec 1;22(23):5696-5705
pubmed: 27542767
Curr Cancer Drug Targets. 2017;17(7):637-649
pubmed: 28359238
Genes Dev. 2012 Jun 1;26(11):1131-55
pubmed: 22661227
Genes Cancer. 2010 Nov;1(11):1124-31
pubmed: 21779436
Cancer Discov. 2016 Jul;6(7):740-53
pubmed: 27217383
Clin Cancer Res. 2012 Jan 15;18(2):568-76
pubmed: 22090362
Nat Commun. 2017 Jun 27;8:15916
pubmed: 28653662
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000
pubmed: 31439820
Br J Cancer. 2011 Jun 7;104(12):1862-8
pubmed: 21610706
Mod Pathol. 2018 Jan;31(1):24-38
pubmed: 29148538
Nature. 2010 Dec 23;468(7327):1074-9
pubmed: 21179163
Cancer Immunol Res. 2020 Sep;8(9):1114-1121
pubmed: 32661093
Cells. 2020 Dec 09;9(12):
pubmed: 33317149
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
Clin Cancer Res. 2015 Jul 1;21(13):2905-10
pubmed: 25941111
Cancer Res. 2016 May 15;76(10):2990-3002
pubmed: 26988987
Cell Cycle. 2020 Jan;19(2):163-178
pubmed: 31885322
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Mol Cell Biol. 2009 Sep;29(17):4623-39
pubmed: 19564413
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Pigment Cell Melanoma Res. 2014 Jul;27(4):590-600
pubmed: 24495407
J Med Genet. 2004 Jun;41(6):421-4
pubmed: 15173226
Cancer Treat Rev. 2016 Apr;45:129-38
pubmed: 27017286
Oncogene. 2004 Jan 8;23(1):201-12
pubmed: 14712225
Clin Cancer Res. 2017 Oct 15;23(20):6138-6150
pubmed: 28751448
Clin Cancer Res. 2017 Nov 15;23(22):6946-6957
pubmed: 28830923
Cell Cycle. 2011 Aug 1;10(15):2497-503
pubmed: 21775818
Int J Mol Sci. 2020 Nov 12;21(22):
pubmed: 33198081
Nat Med. 2012 Oct;18(10):1503-10
pubmed: 22983396
N Engl J Med. 2005 Nov 17;353(20):2135-47
pubmed: 16291983
Pigment Cell Melanoma Res. 2020 Nov;33(6):788-805
pubmed: 32147907
Clin Cancer Res. 2015 Mar 1;21(5):995-1001
pubmed: 25501126
N Engl J Med. 2020 Sep 17;383(12):1139-1148
pubmed: 32877599
Oncogene. 2018 Sep;37(37):5066-5078
pubmed: 29789718
Pathology. 2007 Dec;39(6):551-7
pubmed: 18027257
Int J Cancer. 2018 May 15;142(10):2139-2152
pubmed: 29243224
Mol Cancer Res. 2021 Jun;19(6):991-1004
pubmed: 33707307
Sci Adv. 2019 Sep 18;5(9):eaax6352
pubmed: 31555743
Oncogene. 2017 Jun 8;36(23):3334-3345
pubmed: 28092667
Nat Commun. 2020 Jun 2;11(1):2760
pubmed: 32488085
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1221-5
pubmed: 12538879
Clin Cancer Res. 2019 Nov 1;25(21):6511-6523
pubmed: 31375512
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Adv Cancer Res. 2020;148:147-169
pubmed: 32723562